- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04513925
En studie av Atezolizumab och Tiragolumab jämfört med Durvalumab hos deltagare med lokalt avancerad, icke-resekterbar steg III icke-småcellig lungcancer (NSCLC) (SKYSCRAPER-03)
7 maj 2026 uppdaterad av: Hoffmann-La Roche
En fas III, öppen, randomiserad studie av Atezolizumab och Tiragolumab jämfört med Durvalumab hos patienter med lokalt avancerad, icke-resekterbar, icke-småcellig lungcancer i stadium III som inte har utvecklats efter samtidig platinabaserad kemoradiation
Syftet med denna studie är att utvärdera effektiviteten och säkerheten av atezolizumab i kombination med tirvalumab jämfört med durvalumab hos deltagare med lokalt avancerad, icke-resekterbar steg III icke-småcellig lungcancer (NSCLC) som har fått minst två cykler av samtidig platina- baserad kemoradioterapi (CRT) och har inte haft röntgenologisk sjukdomsprogression.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
829
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Buenos Aires, Argentina, C1431FWO
- CEMIC
-
Ciudad Autonoma Buenos Aires, Argentina, C1284AEB
- Hospital Británico de Buenos Aires
-
Córdoba, Argentina, X5004FHP
- Clínica Universitaria Reina Fabiola
-
Rosario, Argentina, S2000QGB
- Sanatorio Parque S.A.
-
-
-
-
New South Wales
-
Blacktown, New South Wales, Australien, 2148
- Blacktown Hospital
-
Campbelltown, New South Wales, Australien, 2560
- Macarthur Cancer Therapy Centre
-
Kogarah, New South Wales, Australien, 2217
- St George Hospital
-
-
South Australia
-
Bedford Park, South Australia, Australien, 5042
- Flinders Medical Centre
-
-
Victoria
-
Victoria, Victoria, Australien, 3168
- Monash Health Translational Precinct
-
-
Western Australia
-
Bull Creek, Western Australia, Australien, 6149
- Fiona Stanley Hospital
-
-
-
-
-
Charleroi, Belgien, 6000
- GHdC Site Les Viviers
-
Ghent, Belgien, 9000
- AZ Maria Middelares
-
Hasselt, Belgien, 3500
- Jessa Zkh (Campus Virga Jesse)
-
-
-
-
Ceará
-
Fortaleza, Ceará, Brasilien, 60336-550
- CRIO - Centro Regional Integrado de Oncologia
-
-
Paraná
-
Curitiba, Paraná, Brasilien, 80810-050
- Centro Integrado de Oncologia de Curitiba
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brasilien, 98700-000
- Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90610-000
- Hospital Sao Lucas - PUCRS
-
-
São Paulo
-
Barretos, São Paulo, Brasilien, 14784-400
- Hospital de Cancer de Barretos
-
São José do Rio Preto, São Paulo, Brasilien, 15090-000
- Hospital de Base de Sao Jose do Rio Preto
-
São Paulo, São Paulo, Brasilien, 01246-000
- Instituto do Câncer do Estado de São Paulo - ICESP
-
-
-
-
-
Angers, Frankrike, 49933
- CHU Angers
-
Caen, Frankrike, 14000
- Centre François Baclesse
-
Marseille, Frankrike, 13015
- Hopital Nord AP-HM
-
Montpellier, Frankrike, 34070
- Clinique Clementville
-
Vantoux, Frankrike, 57070
- Hôpital Robert Schuman
-
Villejuif, Frankrike, 94805
- Institut Gustave Roussy
-
-
-
-
California
-
Palo Alto, California, Förenta staterna, 94305
- Stanford University
-
-
Colorado
-
Greeley, Colorado, Förenta staterna, 80631
- Banner MD Anderson Cancer Center
-
-
Florida
-
Fort Myers, Florida, Förenta staterna, 33901-8101
- Florida Cancer Specialists
-
Palm Bay, Florida, Förenta staterna, 32901
- Cancer Care Centers of Brevard
-
Pensacola, Florida, Förenta staterna, 32503
- Woodlands Medical Specialists, P.A.
-
St. Petersburg, Florida, Förenta staterna, 33705
- Florida Cancer Specialist, North Region
-
-
Georgia
-
Marietta, Georgia, Förenta staterna, 30060
- Northwest Georgia Oncology Centers PC - Marietta
-
-
Illinois
-
Peoria, Illinois, Förenta staterna, 61615
- Illinois Cancer Care
-
-
Maine
-
Brunswick, Maine, Förenta staterna, 04011
- New England Cancer Specialists
-
-
Massachusetts
-
Fairhaven, Massachusetts, Förenta staterna, 02719
- Southcoast Health System
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55404
- Minnesota Oncology Hematology
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64132
- HCA Midwest Health
-
Springfield, Missouri, Förenta staterna, 65807
- Cox Health Systems
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89128
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Förenta staterna, 89106
- Optum Health Care
-
-
New Jersey
-
East Brunswick, New Jersey, Förenta staterna, 08816
- Titan Health Partners LLC, d/b/a Astera Cancer Care
-
-
New Mexico
-
Farmington, New Mexico, Förenta staterna, 87401
- San Juan Oncology Associates
-
-
New York
-
Albany, New York, Förenta staterna, 12208
- New York Oncology Hematology,P.C.-Albany
-
New York, New York, Förenta staterna, 10029
- Mount Sinai Medical Center
-
The Bronx, New York, Förenta staterna, 10461
- Montefiore Medical Center
-
-
South Carolina
-
Greenville, South Carolina, Förenta staterna, 29615
- Prisma Health ? Upstate
-
-
Tennessee
-
Chattanooga, Tennessee, Förenta staterna, 37403
- Tennessee Oncology Chattanooga
-
Nashville, Tennessee, Förenta staterna, 37203
- Sarah Cannon Research Institute / Tennessee Oncology
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Virginia Cancer Specialists
-
Norfolk, Virginia, Förenta staterna, 23502
- Virginia Oncology Associates
-
-
-
-
-
Asvestochóri, Grekland, 570 10
- General Hospital "G.Papanikolaou"
-
Athens, Grekland, 11527
- Sotiria Hospital
-
Kifissia, Grekland, 145 64
- Agioi Anargyroi Cancer Hospital
-
-
-
-
-
Hong Kong, Hong Kong
- Tuen Mun Hospital
-
Hong Kong, Hong Kong
- Pamela Youde Nethersole Eastern Hospital
-
Hong Kong, Hong Kong, DUMMY_VALUE
- Queen Elizabeth Hospital
-
Hong Kong, Hong Kong, DUMMY_VALUE
- Princess Margaret Hospital, Oncology
-
Pokfulam, Hong Kong, DUMMY_VALUE
- Queen Mary Hospital
-
-
-
-
-
Beersheba, Israel, 8410100
- Soroka Medical Center
-
Haifa, Israel, 3109601
- Rambam Medical Center
-
Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center
-
Petah Tikva, Israel, 4941492
- Rabin Medical Center
-
-
-
-
Campania
-
Naples, Campania, Italien, 80131
- Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italien, 47014
- IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola
-
Parma, Emilia-Romagna, Italien, 43100
- Azienda Ospedaliero Universitaria di Parma
-
-
Lazio
-
Rome, Lazio, Italien, 00128
- Policlinico Universitario Campus Biomedico
-
Rome, Lazio, Italien, 00144
- IRCCS Istituto Regina Elena (IFO)
-
-
Liguria
-
Genoa, Liguria, Italien, 16132
- IRCCS AOU San Martino - IST
-
-
Lombardy
-
Brescia, Lombardy, Italien, 25123
- A.O. Spedali Civili Di Brescia-P.O. Spedali Civili
-
Milan, Lombardy, Italien, DUMMY_VALUE
- Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda)
-
Pavia, Lombardy, Italien, 27100
- Fondazione IRCCS Policlinico San Matteo
-
-
Tuscany
-
Pisa, Tuscany, Italien, 56124
- Azienda Ospedaliera Universitaria Pisana - Ospedale Cisanello
-
-
Veneto
-
Vicenza, Veneto, Italien, 36100
- Azienda ULSS 8 Berica
-
-
-
-
-
Aichi, Japan, 464-8681
- Aichi Cancer Center
-
Chiba, Japan, 277-8577
- National Cancer Center East
-
Hyōgo, Japan, 670-8520
- National Hospital Organization Himeji Medical Center
-
Kanagawa, Japan, 252-0375
- Kitasato University Hospital
-
Kyoto, Japan, 606-8507
- Kyoto University Hospital
-
Miyagi, Japan, 981-0914
- Sendai Kousei Hospital
-
Niigata, Japan, 951-8566
- Niigata Cancer Center Hospital
-
Osaka, Japan, 589-8511
- Kindai University Hospital
-
Saitama, Japan, 362-0806
- Saitama Cancer Center
-
Shizuoka, Japan, 411-8777
- Shizuoka Cancer Center
-
Tokyo, Japan, 104-0045
- National Cancer Center Hospital
-
Tokyo, Japan, 135-8550
- The Cancer Institute Hospital of JFCR
-
Wakayama, Japan, 641-8510
- Wakayama Medical University Hospital
-
-
-
-
British Columbia
-
Abbotsford British Columbia, British Columbia, Kanada, V2S 0C2
- BC Cancer ? Abbotsford
-
Victoria, British Columbia, Kanada, V8R 6V5
- BC Cancer - Victoria
-
-
Ontario
-
Barrie, Ontario, Kanada, L4M 6M2
- Royal Victoria Regional Health Centre
-
Brampton, Ontario, Kanada, L6R 3J7
- William Osler Health System Brampton Civic Hospital
-
Ottawa, Ontario, Kanada, K1H 8L6
- Ottawa Hospital Research Institute
-
-
-
-
-
Beijing, Kina, 101149
- Beijing Chest Hospital
-
Beijing, Kina, 100142
- Beijing Cancer Center
-
Changchun, Kina, 132013
- Jilin cancer hospital
-
Changsha, Kina, 410008
- Xiangya Hospital Central South University
-
Chengdu, Kina, 610041
- Sichuan Provincial Cancer Hospital
-
Chongqing, Kina, 400030
- Chongqing Cancer Hospital
-
Fujian, Kina, 350001
- Fujian Medical University Union Hospital
-
Fuzhou, Kina, 350014
- Fujian Provincial Cancer Hospital
-
Guangzhou, Kina, 510060
- Cancer Center, Sun Yat-sen University of Medical Sciences
-
Hangzhou, Kina, 310002
- Hangzhou Cancer Hospital
-
Jinan, Kina, 250117
- Shandong Cancer Hospital
-
Nanjing, Kina, 210009
- Zhongda Hospital Affiliated to Southeast University
-
Qingdao, Kina, 266042
- The Affiliated Hospital of Qingdao University
-
Shanghai, Kina, 200000
- Shanghai Chest Hospital
-
Shantou, Kina, 515041
- Cancer Hospital of Shantou University Medical College
-
Taiyuan, Kina, 030013
- Shanxi Provincial Cancer Hospital
-
Tianjin, Kina, 300060
- Tianjin Cancer Hospital
-
Wenzhou, Kina, 325000
- The 2nd School of Medicine, WMU
-
Xiamen, Kina, 361003
- The First Affiliated Hospital of Xiamen University
-
Xuzhou, Kina, 221000
- The Affiliated Hospital of Xuzhou Medical College
-
Zhengzhou, Kina, 450008
- Henan Cancer Hospital
-
-
-
-
-
Amersfoort, Nederländerna, 3813 TZ
- Meander Medisch Centrum
-
Breda, Nederländerna, 4819 EV
- Amphia Ziekenhuis
-
Leidschendam, Nederländerna, 2262 BA
- Medisch Centrum Haaglanden, locatie Antoniushove
-
Sittard-Geleen, Nederländerna, 6162 BG
- Zuyderland Medisch Centrum - Sittard Geleen
-
-
-
-
-
Auckland, Nya Zeeland, 1023
- Auckland City Hospital, Cancer and Blood Research
-
-
-
-
-
Gda?sk, Polen, 80-214
- Uniwersyteckie Centrum Kliniczne
-
Olsztyn, Polen, 10-228
- Szpital Kliniczny MSWiA z Warmi?sko-Mazurskim Centrum Onkologii
-
Otwock, Polen, 05-400
- Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy
-
Warsaw, Polen, 02-781
- Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad
-
Wroc?aw, Polen, 53-413
- Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii
-
-
-
-
-
Coimbra, Portugal, 3000-075
- IPO de Coimbra
-
Lisbon, Portugal, 1500-650
- Hospital da Luz
-
Porto, Portugal, 4100-180
- Hospital CUF Porto
-
Porto, Portugal, 4200-072
- IPO do Porto
-
-
-
-
-
A Coruña, Spanien, 15006
- Complejo Hospitalario Universitario A Coruña (CHUAC)
-
Barcelona, Spanien, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, Spanien, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spanien, 28046
- Hospital Universitario La Paz
-
Madrid, Spanien, 28009
- Hospital General Universitario Gregorio Marañón
-
Málaga, Spanien, 29010
- Hospital Regional Universitario Carlos Haya
-
Seville, Spanien, 41013
- Hospital Universitario Virgen del Rocío
-
Seville, Spanien, 41014
- Hospital Univ. Nuestra Señora de Valme
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, Spanien, 07198
- Hospital Son Llatzer
-
-
Barcelona
-
Badalona, Barcelona, Spanien, 08916
- Hospital Universitari Germans Trias i Pujol
-
-
Castellon
-
Castellon, Castellon, Spanien, 12002
- Hospital Provincial de Castellon
-
-
-
-
-
Birmingham, Storbritannien, B9 5SS
- Birmingham Heartlands Hospital
-
Cambridge, Storbritannien, CB2 0QQ
- Addenbrooke's NHS Trust
-
Glasgow, Storbritannien, G12 0YN
- Beatson West of Scotland Cancer Centre
-
Huddersfield, Storbritannien, HD3 3EA
- Calderdale & Huddersfield Nhs Trust
-
Leicester, Storbritannien, LE1 5WW
- Leicester Royal Infirmary
-
Maidstone, Storbritannien, ME16 9QQ
- Maidstone & Tonbridge Wells Hospital
-
Manchester, Storbritannien, M20 4BX
- Christie Foundation Trust
-
Sheffield, Storbritannien, S10 2SJ
- Weston Park Hospital
-
-
-
-
-
Cheongju-si, Sydkorea, 28644
- Chungbuk National University Hospital
-
Daegu, Sydkorea, 41404
- Kyungpook National University Chilgok Hospital
-
Gyeonggi-do, Sydkorea, 13620
- Seoul National University Bundang Hospital
-
Gyeonggi-do, Sydkorea, 16247
- St. Vincent's Hospital
-
Gyeonggi-do, Sydkorea, 10408
- National Cancer Center
-
Gyeonggi-do, Sydkorea, 16499
- Ajou University Medical Center
-
Gyeongsangnam-do, Sydkorea, 50612
- Pusan National University Yangsan Hospital
-
Incheon, Sydkorea, 21565
- Gachon University Gil Medical Center
-
Jeollanam-do, Sydkorea, 58128
- Chonnam National University Hwasun Hospital
-
Seoul, Sydkorea, 03080
- Seoul National University Hospital
-
Seoul, Sydkorea, 05505
- Asan Medical Center
-
Seoul, Sydkorea, 06351
- Samsung Medical Center
-
Seoul, Sydkorea, 08308
- Korea University Guro Hospital
-
Seoul, Sydkorea, 06591
- Seoul St Mary's Hospital
-
Ulsan, Sydkorea, 44033
- Ulsan University Hosiptal
-
-
-
-
-
Taichung, Taiwan, 40447
- China Medical University Hospital
-
Taipei, Taiwan, 112
- Taipei Veterans General Hospital
-
-
-
-
-
Bangkok, Thailand, 10400
- Rajavithi Hospital
-
Bangkok, Thailand, 10300
- Vajira Hospital
-
Bangkok, Thailand, 10400
- Ramathibodi Hospital;Medicine/Oncology
-
Songkhla, Thailand, 90110
- Songklanagarind Hospital
-
-
-
-
-
Adana, Turkiet (Türkiye), 01220
- Adana Baskent University Medical Faculty
-
Ankara, Turkiet (Türkiye), 06500
- Gazi University Medical Faculty, Oncology Hospital
-
Ankara, Turkiet (Türkiye), 06100
- Ankara University Medical Faculty
-
Ankara, Turkiet (Türkiye), 06100
- Hacettepe Universitesi Tip Fakultesi Hastanesi
-
Bornova, ?zm?r, Turkiet (Türkiye), 35100
- Ege University Medical Faculty
-
Diyarbakır, Turkiet (Türkiye), 21280
- Dicle University Faculty of Medicine
-
Edirne, Turkiet (Türkiye), 22030
- Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
-
Istanbul, Turkiet (Türkiye), 34098
- Istanbul University Cerrahpasa Faculty of Medicine
-
Istanbul, Turkiet (Türkiye), 34214
- Medipol University Medical Faculty
-
Malatya, Turkiet (Türkiye), 44280
- Inonu University Faculty of Medicine Turgut Ozal Medical Center
-
-
-
-
-
Braunschweig, Tyskland, 38114
- Klinikum Braunschweig
-
Cologne, Tyskland, 51109
- Klinikum Koeln-Merheim
-
Göttingen, Tyskland, 37075
- Universitaetsmedizin Goettingen
-
Heidelberg, Tyskland, 69126
- Thoraxklinik Heidelberg gGmbH
-
München, Tyskland, 81925
- Klinikum Bogenhausen
-
Regensburg, Tyskland, 93053
- Universitätsklinikum Regensburg
-
-
-
-
-
Pécs, Ungern, 7623
- Pecsi Tudomanyegyetem
-
Tatabánya, Ungern, 2800
- Szent Borbala Korhaz
-
Törökbálint, Ungern, 2045
- Tudogyogyintezet Torokbalint
-
-
-
-
-
Innsbruck, Österrike, 6020
- Tiroler Landeskrankenanstalten Ges.M.B.H.
-
Linz, Österrike, 4020
- Kepler Universitätskliniken GmbH - Med Campus III
-
Vienna, Österrike, 1140
- Klinik Penzing
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Beskrivning
Inklusionskriterier:
- Eastern Cooperative Oncology Group (ECOG) prestationsstatus på 0 eller 1
- Histologiskt eller cytologiskt dokumenterad NSCLC med lokalt avancerad, ooperbar steg III NSCLC av antingen skivepitelvävnad eller icke-skivepitelhistologi
- Helkropps positronemissionstomografi-datortomografi (PET-CT) skanning, utförd före och inom 42 dagar efter den första dosen av samtidig kemoradioterapi (cCRT)
- Minst två tidigare cykler av platinabaserad kemoterapi administrerad samtidigt med strålbehandling (RT), som måste slutföras inom 1 till 42 dagar före randomisering i studien (en cykel av cCRT definieras som 21 eller 28 dagar)
- Strålbehandlingskomponenten (RT) i cCRT måste ha haft en total stråldos på 60 (±10 procent [%)) grå (Gy) (54 Gy till 66 Gy) administrerad med intensitetsmodulerad RT (föredraget) eller 3D- överensstämmande teknik
- Ingen progression under eller efter samtidig platinabaserad CRT
- Ett känt PD-L1-resultat
- Förväntad livslängd >/= 12 veckor
- Tillräcklig hematologisk funktion och ändorgansfunktion
- Kvinnliga deltagare måste vara villiga att undvika graviditet i 90 dagar efter den sista dosen av tirvalumab och 5 månader efter den sista dosen av atezolizumab, eller i 3 månader efter den sista dosen av durvalumab
- Manliga deltagare måste förbli abstinenta eller använda kondom under behandlingsperioden och i 90 dagar efter den sista dosen av tiragolumab
- Manliga deltagare får inte donera spermier under behandlingsperioden och under 90 dagar efter den sista dosen av tiragolumab
Exklusions kriterier:
- Någon historia av tidigare NSCLC och/eller någon historia av tidigare behandling för NSCLC (deltagare måste nyligen diagnostiseras med icke-operabel sjukdom i steg III)
- NSCLC känd för att ha en mutation i genen för epidermal tillväxtfaktorreceptor (EGFR) eller en anaplastiskt lymfomkinas (ALK) fusionsonkogen
- Alla tecken på sjukdom i steg IV
- Behandling med sekventiell CRT för lokalt avancerad NSCLC
- Deltagare med lokalt avancerad NSCLC som har utvecklats under eller efter den definitiva cCRT före randomisering
- Eventuell olöst toxicitet av grad >2 från tidigare CRT
- Grad >= 2 pneumonit från tidigare CRT
- Aktiv eller historia av autoimmun sjukdom eller immunbrist
- Historik av idiopatisk lungfibros, organiserande lunginflammation, läkemedelsinducerad pneumonit eller idiopatisk pneumonit eller tecken på aktiv pneumonit
- Andra maligniteter i anamnesen än NSCLC inom 5 år före screening med undantag för maligniteter med en försumbar risk för metastaser eller dödsfall
- Tidigare allogen stamcells- eller fasta organtransplantation
- Aktiv Epstein-Barr-virusinfektion (EBV) eller känd eller misstänkt kronisk aktiv EBV-infektion vid screening
- Behandling med undersökningsterapi inom 28 dagar innan studiebehandlingen påbörjas
- Tidigare behandling med CD137-agonister eller immunkontrollpunktsblockadterapier, inklusive anti-cytotoxiskt T-lymfocytassocierat protein 4, anti-T-cells immunoreceptor med Ig- och ITIM-domäner (anti-TIGIT), anti-PD-1 och anti-PD-L1
- Alla tidigare immunförmedlade biverkningar av grad >/= 3 eller olösta immunförmedlade biverkningar av grad > 1 medan man fått något tidigare immunterapimedel förutom immunkontrollpunktblockader
- Behandling med systemisk immunsuppressiv medicin
- Kvinnor som är gravida eller ammar
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Atezolizumab + Tiragolumab
Deltagarna kommer att få atezolizumab administrerat intravenöst (IV) på dag 1 av varje 28-dagarscykel följt av tiragolumab administrerat IV på dag 1 av varje 28-dagarscykel under maximalt 13 cykler.
|
Atezolizumab 1680 mg var 4:e vecka (Q4W) kommer att administreras IV på dag 1 i varje 28-dagarscykel.
Andra namn:
Tiragolumab 840 mg Q4W kommer att administreras IV på dag 1 i varje 28-dagarscykel.
Andra namn:
|
|
Aktiv komparator: Durvalumab
Deltagarna kommer att få durvalumab administrerat IV under varje 28-dagarscykel under maximalt 13 cykler.
|
Durvalumab kommer att administreras baserat på vikt vid 10 mg/kg IV varannan vecka (Q2W) på dag 1 och 15 i varje 28-dagarscykel, eller kommer att administreras i en fast dos på 1500 mg IV var 4:e vecka (Q4W) ( för deltagare vars vikt >/= 30 kg) på dag 1 av varje 28-dagars cykel.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)
Tidsram: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by an IRF according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions.
Kaplan-Meier (K-M) method was used to estimate median PFS.
|
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
PFS, as Assessed by an IRF in FAS
Tidsram: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate median PFS.
|
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Survival (OS) in PPAS
Tidsram: From randomization to death from any cause (up to approximately 57 months)
|
OS was defined as the time from randomization to death from any cause.
K-M method was used to estimate median OS.
|
From randomization to death from any cause (up to approximately 57 months)
|
|
PFS, as Assessed by the Investigator in PPAS
Tidsram: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate median PFS.
|
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
Confirmed Objective Response Rate (ORR), as Assessed by an IRF in PPAS
Tidsram: Up to approximately 57 months
|
ORR was defined as the percentage of participants who achieved an objective response (OR), characterized by a complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by an IRF according to RECIST v1.1.
CR was defined as disappearance of all target and non-target lesion & normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
Percentages have been rounded off.
|
Up to approximately 57 months
|
|
Confirmed ORR, as Assessed by the Investigator in PPAS
Tidsram: Up to approximately 57 months
|
ORR was defined as the percentage of participants who achieved an OR, characterized by CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1.
CR was defined as disappearance of all target and non-target lesions & normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
Percentages have been rounded off.
|
Up to approximately 57 months
|
|
Duration of Response (DOR), as Assessed by an IRF in PPAS
Tidsram: From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
DOR was defined as the time from the first occurrence of a confirmed OR, characterized by CR or PR, until the first date of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first.
CR was defined as disappearance of all target and non-target lesions & normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
Median DOR was estimated using the K-M method.
|
From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
DOR, as Assessed by the Investigator in PPAS
Tidsram: From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
DOR was defined as the time from the first occurrence of a confirmed OR, characterized by CR or PR, until the first date of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
CR was defined as disappearance of all target and non-target lesions, normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
Median DOR was estimated using the K-M method.
|
From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
Time to Confirmed Deterioration (TTCD) in Cough, as Assessed Using European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) in PPAS
Tidsram: Up to approximately 57 months
|
TTCD=time from randomization until first confirmed clinically meaningful deterioration (CCMD) on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Cough scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Dyspnoea, as Assessed Using EORTC QLQ-LC13 in PPAS
Tidsram: Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Dyspnoea was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Chest Pain, as Assessed Using EORTC QLQ-LC13 in PPAS
Tidsram: Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Chest pain was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Global Health Status (GHS)/Quality-of-life (QoL), as Assessed Using European Organisation for Research and Treatment of Cancer Quality-of-life Core-30 (EORTC QLQ-C30) in PPAS
Tidsram: Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea, vomiting, & pain), GHS/QoL, & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties).
GHS/QoL questions were scored on 7-point scale with scores ranging from 1=Very poor to 7=Excellent.
Scores were linearly transformed to a score range of 0-100.
High score for GHS/QoL scale=better health-related quality-of-life (HRQoL).
CCMD=decrease from baseline (≥10 points) in GHS/QoL scale score, held for at least 2 consecutive assessments/initial clinically meaningful decrease above baseline followed by death within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Physical Functioning (PF), as Assessed Using EORTC QLQ-C30 in PPAS
Tidsram: Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea, vomiting, & pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties).
PF was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to a score range of 0-100.
High score for PF=high/healthy level of functioning.
CCMD=decrease from baseline (≥10 points) in PF score, held for at least 2 consecutive assessments or initial clinically meaningful decrease above baseline followed by death within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
OS in FAS
Tidsram: From randomization to death from any cause (up to approximately 57 months)
|
OS was defined as the time from randomization to death from any cause.
K-M method was used to estimate median OS.
|
From randomization to death from any cause (up to approximately 57 months)
|
|
PFS, as Assessed by the Investigator in FAS
Tidsram: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate median PFS.
|
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
Confirmed ORR, as Assessed by an IRF in FAS
Tidsram: Up to approximately 57 months
|
ORR was defined as the percentage of participants who achieved an OR, characterized by CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by an IRF according to RECIST v1.1.
CR was defined as disappearance of all target and non-target lesions, normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
Percentages have been rounded off.
|
Up to approximately 57 months
|
|
Confirmed ORR, as Assessed by the Investigator in FAS
Tidsram: Up to approximately 57 months
|
ORR was defined as the percentage of participants who achieved an OR, characterized by a CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1.
CR was defined as disappearance of all target and non-target lesions, normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
Percentages have been rounded off.
|
Up to approximately 57 months
|
|
DOR, as Assessed by an IRF in FAS
Tidsram: From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
DOR was defined as the time from the first occurrence of a confirmed OR, characterized by CR or PR, until the first date of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first.
CR was defined as disappearance of all target and non-target lesions, normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
Median DOR was estimated using the K-M method.
|
From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
DOR, as Assessed by the Investigator in FAS
Tidsram: From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
DOR was defined as the time from the first occurrence of a confirmed OR, characterized by CR or PR, until the first date of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
CR was defined as disappearance of all target and non-target lesions, normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
Median DOR was estimated using the K-M method.
|
From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
TTCD in Cough, as Assessed Using EORTC QLQ-LC13 in FAS
Tidsram: Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Cough was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Dyspnoea, as Assessed Using EORTC QLQ-LC13 in FAS
Tidsram: Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Dyspnoea was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Chest Pain, as Assessed Using EORTC QLQ-LC13 in FAS
Tidsram: Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Chest pain was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in GHS/QoL, as Assessed Using EORTC QLQ-C30 in FAS
Tidsram: Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea, vomiting, & pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties).
GHS/QoL questions were scored on 7-point scale with scores ranging from 1=Very poor to 7=Excellent.
Scores were linearly transformed to a score range of 0-100.
High score for GHS/QoL scale=better HRQoL.
CCMD=decrease from baseline (≥10 points) in GHS/QoL scale score, held for at least 2 consecutive assessments or initial clinically meaningful decrease above baseline followed by death within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in PF, as Assessed Using EORTC QLQ-C30 in FAS
Tidsram: Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea, vomiting, & pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties).
PF was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to a score range of 0-100.
High score for PF=high/healthy level of functioning.
CCMD=decrease from baseline (≥10 points) in PF score, held for at least 2 consecutive assessments or initial clinically meaningful decrease above baseline followed by death within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
PFS Rate at 12, 18, and 24 Months, as Assessed by an IRF in PPAS
Tidsram: At Months 12, 18, and 24
|
PFS rate at 12, 18, and 24 months was defined as the percentage of participants who did not experience PD or death from any cause, as determined by an IRF, at 12, 18, and 24 months.
PFS was defined as the time from randomization to the first occurrence of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate median PFS rate.
Percentages have been rounded off.
|
At Months 12, 18, and 24
|
|
PFS Rate at 12, 18, and 24 Months, as Assessed by the Investigator in PPAS
Tidsram: At Months 12, 18, and 24
|
PFS rate at 12, 18, and 24 months was defined as the percentage of participants who did not experience PD or death from any cause, as determined by the investigator, at 12, 18, and 24 months.
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate median PFS rate.
Percentages have been rounded off.
|
At Months 12, 18, and 24
|
|
OS Rate at 12, 24, 36, and 48 Months in PPAS
Tidsram: At Months 12, 24, 36, and 48
|
OS rate at months 12, 24, 36 and 48 was defined as percentage of participants who did not experience death from any cause at the specified timepoints.
OS was defined as the time from randomization to death from any cause.
K-M method was used to estimate OS rate.
Percentages have been rounded off.
|
At Months 12, 24, 36, and 48
|
|
Time-to-distant Metastasis (TTDM), as Assessed by the Investigator in PPAS
Tidsram: Up to approximately 57 months
|
TTDM was defined as the time from the date of randomization until the date of first documented distant metastasis, as assessed by investigator according to RECIST v1.1, or death, whichever occurred first.
Distant metastasis was defined as any new lesion that was outside of the radiation field.
K-M method was used to estimate median TTDM.
|
Up to approximately 57 months
|
|
PFS Rate at 12, 18, and 24 Months, as Assessed by an IRF in FAS
Tidsram: At Months 12, 18, and 24
|
PFS rate at 12, 18, and 24 months was defined as the percentage of participants who did not experience PD or death from any cause, as determined by an IRF, at 12, 18, and 24 months.
PFS was defined as the time from randomization to the first occurrence of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate PFS rate.
Percentages have been rounded off.
|
At Months 12, 18, and 24
|
|
PFS Rate at 12, 18, and 24 Months, as Assessed by the Investigator in FAS
Tidsram: At Months 12, 18, and 24
|
PFS rate at 12, 18, and 24 months was defined as the percentage of participants who did not experience PD or death from any cause, as determined by the investigator, at 12, 18, and 24 months.
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate PFS rate.
Percentages have been rounded off.
|
At Months 12, 18, and 24
|
|
OS Rate at 12, 24, 36, and 48 Months in FAS
Tidsram: At Months 12, 24, 36, and 48
|
OS rate at months 12, 24, 36 and 48 was defined as percentage of participants who did not experience death from any cause at the specified timepoints.
OS was defined as the time from randomization to death from any cause.
K-M method was used to estimate OS rate.
Percentages have been rounded off.
|
At Months 12, 24, 36, and 48
|
|
TTDM, as Assessed by the Investigator in FAS
Tidsram: Up to approximately 57 months
|
TTDM was defined as the time from the date of randomization until the date of first documented distant metastasis, as assessed by investigator according to RECIST v1.1, or death, whichever occurred first.
Distant metastasis was defined as any new lesion that was outside of the radiation field.
K-M method was used to estimate median TTDM.
|
Up to approximately 57 months
|
|
Number of Participants With Adverse Events (AEs)
Tidsram: Up to approximately 24.7 months
|
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product.
|
Up to approximately 24.7 months
|
|
Number of Participants With Cytokine Release Syndrome (CRS)
Tidsram: Up to approximately 24.7 months
|
CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells.
Symptoms may be progressive, including fever at onset, and may also include hypotension, capillary leak (hypoxia), and end-organ dysfunction.
|
Up to approximately 24.7 months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Studierektor: Clinical Trials, Hoffmann-La Roche
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
24 augusti 2020
Primärt slutförande (Faktisk)
27 maj 2025
Avslutad studie (Faktisk)
31 juli 2025
Studieregistreringsdatum
Först inskickad
13 augusti 2020
Först inskickad som uppfyllde QC-kriterierna
13 augusti 2020
Första postat (Faktisk)
14 augusti 2020
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
3 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
7 maj 2026
Senast verifierad
1 maj 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Luftvägssjukdomar
- Lungsjukdomar
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Lungneoplasmer
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Karcinom, icke-småcellig lunga
- Antineoplastiska medel, immunologiska
- Immune Checkpoint-hämmare
- Antineoplastiska medel
- Molekylära mekanismer för farmakologisk verkan
- durvalumab
- atezolizumab
- Tiragolumab
Andra studie-ID-nummer
- GO41854
- 2019-004773-29 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
Kvalificerade forskare kan begära tillgång till data på individuell patientnivå via plattformen för begäran om kliniska studier (www.vivli.org).
Ytterligare information om Roches kriterier för kvalificerade studier finns här (https://vivli.org/members/ourmembers/). För ytterligare information om Roches globala policy för delning av klinisk information och hur man begär åtkomst till relaterade kliniska studiedokument, se här (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Ja
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .